(Alliance News) - Physiomics PLC said Monday it has signed a further contract with an existing biotech client, Cambridge, England-based CellCentric.
Physiomics shares were up 3.6% in London at 2.80 pence each on Monday.
The oncology consultancy company did not disclose the value of the contract, but said it is expected to be completed in the first half of 2020.
The project will involve pharmacokinetic and pharmacodynamic modelling and build on the work completed over the course of 2019 in support of the clinical development of CellCentric's lead asset CCS1477, the company said.
Jim Millen, chief executive officer, said: "We are looking forward to continuing to work with CellCentric, one of the UK's most exciting young biotech companies."
By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)